Lege artis - Das Magazin zur ärztlichen Weiterbildung, Table of Contents PSYCH up2date 2014; 8(01): 37-48DOI: 10.1055/s-0033-1359999 Essstörungen, somatische Belastungsstörungen, Schlafstörungen und sexuelle Funktionsstörungen Medikamentöse Behandlungsstrategien bei chronischen Schmerzen Schwerpunkt antihyperalgetisch wirksame Substanzen Michael Stephan , Matthias Karst , Michael Bernateck Recommend Article Abstract Buy Article Full Text References Literatur 1 International Association for the Study of Pain I. Report of subcommittee on taxonomy. Pain 1979; 6: 249-252 2 Merkey H. An investigation of pain in psychological illness. Oxford: DM thesis; 1964 3 Bryant RA, Creamer M, O’Donnell M. et al. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry 2009; 65: 438-440 4 Holbrook TL, Hoyt DB, Coimbra R. et al. Long-term posttraumatic stress disorder persists after major trauma in adolescents: new data on risk factors and functional outcome. J Trauma 2005; 58: 764-769 5 Norman SB, Stein MB, Dimsdale JE. et al. Pain in the aftermath of trauma is a risk factor for post-traumatic stress disorder. Psychol Med 2008; 38: 533-542 6 Gerbershagen HJ. Transition from acute to chronic postsurgical pain. Physiology, risk factors, and prevention. Schmerz 2013; 27: 81-93 7 Stephan M, Helfritz F, Pabst R. et al. Postnatally induced differences in adult pain sensitivity depends on genetics, gender, and specific experiences: Reversal of maternal deprivation effects by additional postnatal tactile stimulation or chronic imipramine treatment. Behav Brain Res 2002; 133: 149-158 8 Langley PC. The prevalence, correlates, and treatment of pain in the European Union. Curr Med Res Opin 2011; 27: 463-480 9 Dietl M, Korczak D. HTA-Bericht 111. Versorgungssituation in der Schmerztherapie in Deutschland im internationalen Vergleich hinsichtlich Über-, Unter- oder Fehlversorgung. Köln: DIMDI; 2011. [ISSN: 1864-9645] 10 Garcia-Cebrian A, Gandhi P, Demyttenaere K. et al. The association of depression and painful physical symptoms – a review of the European literature. Eur Psychiatry 2006; 21: 379-388 11 Langley P, Müller-Schwefe G, Nicolaou A. et al. The impact of pain on labor force participation, absenteeism, and presenteeism in the European Union. J Med Econ 2010; 13: 662-672 12 Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011; 152: S2-S15 13 Maihöfner C, Nickel FT, Seifert F. Neuropathische Schmerzsyndrome und Neuroplastizität in der funktionellen Bildgebung. Schmerz 2010; 24: 137-145 14 Hucho T, Suckow V, Joseph EK. et al. Ca++/CaMKII switches nociceptor-sensitizing stimuli into desensitizing stimuli. J Neurochem 2012; 123: 589-601 15 Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007; 369: 946-955 16 Beal MC. Viscero-somatic reflexes: a review. J Am Osteopathol Acad 1985; 85: 786-801 17 Hess A, Axmann R, Rech J. et al. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA 2011; 108: 3731-3736 18 Schünke M, Schulte E, Schumacher U. Prometheus. LernAtlas der Anatomie. Kopf, Hals und Neuroanatomie. Illustrationen von M. Voll und K. Wesker. 3 Aufl.. Stuttgart: Thieme; 2012 19 Jensen TS, Baron R, Haanpää M. et al. A new definition of neuropathic pain. Pain 2011; 152: 2204-2205 20 Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573-581 21 Hennigsen P, Derra C, Türp JC. et al. Funktionelle somatische Schmerzsyndrome. Schmerz 2004; 18: 126-140 22 Hoffmann BM, Papas RK, Chatkoff DK. et al. Meta-Analysis of psychological interventions for chronic low back pain. Health Psychology 2007; 26: 1-9 23 Pfingsten M, Arnold B, Nagel B. et al. Effektivität intensiver multimodaler Schmerztherapie-Programme. Schmerz 2010; 24: 172-176 24 Dworkin RH, O’Connor AB, Backonja M. et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 132: 237-251 25 AWMF-Leitlinien-Register Nr. 041/003, Entwicklungsstufe 3. Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen. 06/2009 26 Zernikow B, Gerhold K, Bürk G. et al. Definition, diagnosis and therapy of chronic widepread pain and so-called fibromyalgia syndrome in children and adolescents. Systematic literature review and guideline. Schmerz 2012; 26: 318-330 27 Göbel H. Innovative integrated and coordinated care in pain therapy. Schmerz 2013; 27: 120-122 28 Mercier A, Auger-Aubin I, Lebeau JP. et al. Evidence of prescription of antidepressants for non-psychiatric conditions in primary care: an analysis of guidelines and systemativ reviews. BMC Fam Pract 2013; 14: 55 29 McCleane G. Antidepressants as analgesics. CNS Drugs 2008; 22: 139-156 30 Evers S, May A, Fritsche G. et al. Akuttherapie und Prophylaxe der Migräne – Leitlinie der Deutschen Migräne- und Kopfschmerzgesellschaft und der Deutschen Gesellschaft für Neurologie. Nervenheilkunde 2008; 27: 933-949 31 Bigal ME, Rapoport AM, Hargreaves R. Advances in the pharmacologic treatment of tension-type headache. Curr Pain Headache 2008; 12: 442-446 32 Ford AC, Talley NJ, Schoenfeld PS. et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-378 33 Argoff CE. Topical analgesics in the management of acute and chronic pain. Mayo Clinic Proceedings 2013; 88: 195-205 34 Geller DA, Biederman J, Stewart SE. et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003; 160: 1919-1928 35 Rahimi R, Nikfar S, Rezaie A. et al. Efficacy of tricyclic antidepressant in irritable bowel syndrome: A meta-analysis. World J Gastroenterol 2009; 15: 1548-1553 36 Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry 2008; 5: 16-19 37 Greaves MW. Recent advances in pathophysiology and current management of itch. Ann Acad Med Singapore 2007; 36: 788-792 38 Spielmans GI. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychother Psychosom 2008; 77: 12-16 39 Moore RA, Cai N, Skljarevski V. et al. Duloxetine use in chronic painful conditions – individual patient data responder analysis. Eur J Pain 2013; [Epub ahead of print]. 40 European Medicines Agency. Summary of the European Public Assessment Report. Im Internet: Accessed December 11, 2013 at: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000572/human_med_000732.jsp 41 Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects – a possible opioid involvement in severe depression?. J Mol Neurosci 2002; 18: 143-149 42 Shah TH, Moradimehr A. Bupropion for the treatment of neuropathic pain. Am J Hosp Palliat Care 2010; 27: 333-336 43 Serretti A, Mandelli L. Antidepressants and body weight: A comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-1272 44 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF). Leitlinie „Chronische neuropathische Schmerzen, Pharmakologische nicht interventionelle Therapie“. Im Internet: Accessed December 11, 2013 at: http://www.awmf.org/leitlinien/detail/ll/030-114.html 45 Moore AR, Eccleston C, Derry S. et al. ACTINPAIN writing group of the IASP special interest group on systematic reviews in pain relief; Cochrane Pain, palliative and supportive care systematic review group editors. Pain 2010; 150: 386-389 46 Clarke H, Bonin RP, Orser BA. et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesth Analg 2012; 115: 428-442 47 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF). Leitlinien für Diagnostik und Therapie in der Neurologie: Trigeminusneuralgie. Im Internet: Accessed December 11, 2013 at: http://www.awmf.org/uploads/tx_szleitlinien/030-016l_S1_Trigeminusneuralgie_2012.pdf 48 Block F, Habermeyer B. Glutamatantagonisten bei neuropathischen Schmerzen. Schmerz 2003; 17: 261-267 49 Tam E, Furlan AD. Transdermal lidocaine and ketamine for neuropathic pain: a study of effectiveness and tolerability. Open Neuol J 2012; 6: 58-64 50 Niesters M, Dahan A. Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain. Expert Opin Drug Metab Toxicol 2012; 8: 1409-1417 51 Zarate C, Duman RS, Liu G. et al. New paradigms for treatment-resistant depression. Ann N Y Acad Sci 2013; 1292: 21-31 52 Arzneimittelkommission der deutschen Ärzteschaft. Einschränkung der therapeutischen Zielgruppe und Begrenzung der Behandlungsdauer für Flupirtin-haltige Arzneimittel nach Bewertung des Lebertoxizitätsrisikos. Im Internet: Accessed December 11, 2013 at: http://www.akdae.de/Arzneimittelsicherheit/RHB/20130716.pdf
